The same experiment in A549 cells confirmed this result in the lung cancer cell line – compared to iRhom2WT, expressing iRhom2D188N in A549-DKO cells caused a more than two-fold increase in the release of endogenous amphiregulin in the presence of oncogenic KRAS (Fig. 6A,B), indicating that tylotic mutation sensitises iRhom2 to oncogenic signalling. Here, RHBDF2 is linked to lung carcinoma.